Mavelertinib

Mavelertinib is an oral epidermal growth factor receptor (EGFR) mutant T790M inhibitor with potential anti-tumor activity. Mavelertinib specifically binds and inhibits EGFR T790M, a secondary resistance mutation that blocks EGFR-mediated signaling and causes death of EGFR T790M-expressing tumor cells. Compared with some other EGFR inhibitors, PF-06747775 may have therapeutic benefit in tumors with T790M-mediated resistance.

• Supplier: Alfa Cytology
• Product #: BC0406